New Drug Pricing Deals and Cancer Therapy Approved

In a significant move, Bayer, Takeda, and CSL Behring are among several pharmaceutical companies involved in new drug pricing agreements anticipated to be announced by the White House on Monday. These deals, reported by the Financial Times, aim to secure concessions from drugmakers in exchange for financial relief.

Additionally, the FDA has granted approval to the drug Mimrylo, developed by Takeda and Protagonist, for treating polycythemia vera, a slow-growing cancer characterized by excessive red blood cell production. Specific pricing details remain undisclosed.

Source: www.statnews.com